131 related articles for article (PubMed ID: 37702631)
1. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
2. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
[TBL] [Abstract][Full Text] [Related]
3. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
Dacic S; Travis WD; Giltnane JM; Kos F; Abel J; Hilz S; Fujimoto J; Sholl L; Ritter J; Khalil F; Liu Y; Taylor-Weiner A; Resnick M; Yu H; Hirsch FR; Bunn PA; Carbone DP; Rusch V; Kwiatkowski DJ; Johnson BE; Lee JM; Hennek SR; Wapinski I; Nicholas A; Johnson A; Schulze K; Kris MG; Wistuba II
J Thorac Oncol; 2024 May; 19(5):719-731. PubMed ID: 38070597
[TBL] [Abstract][Full Text] [Related]
4. Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice.
Saqi A; Leslie KO; Moreira AL; Lantuejoul S; Shu CA; Rizvi NA; Sonett JR; Tajima K; Sun SW; Gitlitz BJ; Colby TV
JTO Clin Res Rep; 2022 May; 3(5):100310. PubMed ID: 35498382
[TBL] [Abstract][Full Text] [Related]
5. Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer.
Yuan P; Guo C; Li L; Ling Y; Guo L; Ying J
BMC Med; 2022 Oct; 20(1):403. PubMed ID: 36280845
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
7. Deep Learning for Predicting Effect of Neoadjuvant Therapies in Non-Small Cell Lung Carcinomas With Histologic Images.
Terada K; Yoshizawa A; Liu X; Ito H; Hamaji M; Menju T; Date H; Bise R; Haga H
Mod Pathol; 2023 Nov; 36(11):100302. PubMed ID: 37580019
[TBL] [Abstract][Full Text] [Related]
8. Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer.
Dacic S
Surg Pathol Clin; 2024 Jun; 17(2):287-293. PubMed ID: 38692811
[TBL] [Abstract][Full Text] [Related]
9. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
[TBL] [Abstract][Full Text] [Related]
10. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
[TBL] [Abstract][Full Text] [Related]
12. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG
Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125
[TBL] [Abstract][Full Text] [Related]
13. [Pathological assessment of non-small cell lung cancer resection specimens after neoadjuvant therapy].
Huang Y; Zhang LP; Hou LK; Dong ZW; Zhang W; Wu W; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):773-778. PubMed ID: 34405613
[No Abstract] [Full Text] [Related]
14. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
[TBL] [Abstract][Full Text] [Related]
15. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
16. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
17. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
18. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
Zhang Y; Fu F; Hu H; Wang S; Li Y; Hu H; Chen H
J Thorac Cardiovasc Surg; 2021 Feb; 161(2):434-442.e2. PubMed ID: 32340810
[TBL] [Abstract][Full Text] [Related]
20. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Travis WD; Dacic S; Wistuba I; Sholl L; Adusumilli P; Bubendorf L; Bunn P; Cascone T; Chaft J; Chen G; Chou TY; Cooper W; Erasmus JJ; Ferreira CG; Goo JM; Heymach J; Hirsch FR; Horinouchi H; Kerr K; Kris M; Jain D; Kim YT; Lopez-Rios F; Lu S; Mitsudomi T; Moreira A; Motoi N; Nicholson AG; Oliveira R; Papotti M; Pastorino U; Paz-Ares L; Pelosi G; Poleri C; Provencio M; Roden AC; Scagliotti G; Swisher SG; Thunnissen E; Tsao MS; Vansteenkiste J; Weder W; Yatabe Y
J Thorac Oncol; 2020 May; 15(5):709-740. PubMed ID: 32004713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]